title: Liver toxicity induced by combined external-beam irradiation and radioimmunoglobulin therapy.
abstract: High-dose radiation therapy for liver metastases of gastrointestinal malignancies might be improved by combining external-beam irradiation and radioimmunoglobulin therapy. We studied the liver toxicity of the proposed combination in healthy beagle dogs. A total dose of 30 Gy to the whole liver, delivered in 2-Gy fractions over 3 weeks, resulted in mild, temporary veno-occlusive disease (VOD) in three of three dogs. Reversible bone marrow damage was noted after two intravenous injections of 18.5 MBq of yttrium-90-labeled monoclonal antibody ZCE025 per kg body weight in three of three dogs. Administrations of the antibody were separated by 1 week. Three dogs treated by irradiation of the liver with radioimmunoglobulin therapy added during the last 2 weeks of the irradiation showed signs of radiation hepatitis (VOD) starting around 35 days after treatment. One dog had a complete recovery, and two dogs were euthanized in a stage of terminal liver failure around day 90 after treatment. Temporary bone marrow damage was observed after the combined treatment, similar to the bone marrow damage observed after radioimmunoglobulin therapy alone. Earlier studies in the same dog model showed that bone marrow is the dose-limiting organ if radioimmunoglobulin therapy is used alone. The addition of irradiation of the liver to radioimmunoglobulin therapy changes the dose-limiting organ from bone marrow to liver. The radiation hepatitis observed in dogs is very similar to that observed in humans and is reflected in early platelet consumption in the irradiated liver plus late elevations of liver enzymes and VOD in central hepatic veins on histological analysis. Future applications of combined liver irradiation and radioimmunoglobulin therapy in humans should use radioimmunoglobulin therapy agents which show minimal uptake by normal liver.
authors.affiliation: Department of Experimental Radiotherapy, University of Texas M.D. Anderson Cancer Center, Houston 77030.
authors.forename: S
authors.initials: S
authors.lastname: Wang
authors.forename: S M
authors.initials: SM
authors.lastname: Quadri
authors.forename: X Z
authors.initials: XZ
authors.lastname: Tang
authors.forename: L C
authors.initials: LC
authors.lastname: Stephens
authors.forename: C P
authors.initials: CP
authors.lastname: Lollo
authors.forename: R M
authors.initials: RM
authors.lastname: Bartholomew
authors.forename: H M
authors.initials: HM
authors.lastname: Vriesendorp
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004285:Dogs; D005260:Female; D007205:Indium Radioisotopes / Q000493:pharmacokinetics; D008099:Liver / Q000528:radiation effects*; D008297:Male; D016499:Radioimmunotherapy / Q000009:adverse effects; D015021:Yttrium Radioisotopes / Q000493:pharmacokinetics
chemical_list: D000911:Antibodies, Monoclonal; D007205:Indium Radioisotopes; D015021:Yttrium Radioisotopes